River Blindness or onchocerciasis is caused by the prelarval (microfilaria) and adult stages of the filarial nematode Onchocerca volvulus. The disease is transmitted by the bite of certain species of female Simulium flies (black flies) that bite by day and are found near rapidly flowing rivers and streams. Onchocerciasis is endemic in more than 25 nations located in a broad band across the central part of Africa. Small endemic foci are also present in the Arabian Peninsula (Yemen) and in the Americas (Brazil, Colombia, Ecuador, Guatemala, southern Mexico, and Venezuela)
Researchers in London, UK, have identified several compounds with SARS-CoV-2 inhibiting properties, that potentially may be developed into antiviral solutions in the future.
Global campaigns to eliminate two tropical parasitic worm infections have been hindered by a lack of good diagnostic tools.
The discovery of new drugs is vital to achieving the eradication of neglected tropical diseases (NTDs) in Africa and around the world.
A report on onchocerciasis (also known as river blindness) shows continued global progress towards achieving interruption of transmission of the disease.
Illustrations by a local artist in Nigeria are helping health workers and policy makers understand what it's really like to live with a neglected tropical disease (NTD).
A new study published on the preprint server bioRxiv reports the elucidation of the mechanism of inhibition of SARS-CoV-2 by a non-nucleotide inhibitor called suramin. This is the first such compound to be shown to have such activity and shows promise for use as a repurposed drug against COVID-19.
Researchers have developed a method to spur the production of new antibiotic or antiparasitic compounds hiding in the genomes of actinobacteria, which are the source of drugs such as actinomycin and streptomycin and are known to harbor other untapped chemical riches.
Efforts to eliminate river blindness, a debilitating disease affecting millions in Africa, will be hampered by another parasitic infection known as Loiasis, or 'African eye worm,' according to a study published in Clinical Infectious Diseases.
Researchers at the LSTM's Centre for Drugs and Diagnostics, and University of Buea, Cameroon have developed new models of the tropical eye worm, Loa loa for the development of new drugs against filariasis.
The microorganisms that cause malaria, leishmaniasis and a variety of other illnesses today can be traced back at least to the time of dinosaurs, a study of amber-preserved blood-sucking insects and ticks show.
TGen North, the Pathogen and Microbiome Division of the Translational Genomics Research Institute, has partnered with the non-profit NARBHA Institute to advance human health through the new TGen One Health Collaborative, an initiative that recognizes the interdependence of people, animals and plants in both the human-built and natural environments.
Scientists at Scripps Research have developed a urine diagnostic to detect the parasitic worms that cause river blindness, also called onchocerciasis, a tropical disease that afflicts 18 to 120 million people worldwide.
River blindness and elephantiasis are debilitating diseases caused by parasitic worms that infect as many as 150 million people worldwide.
The Berkeley researchers figured out that they could quickly determine who has the Loa loa worm using a smartphone, customized to work like a microscope. They could then skip the medication for those people and give it to everyone else. Kamgno, who received the latest version of the phones in 2016, dubbed the mobile microscopes "revolutionary."
River blindness, or onchocerciasis, is a disease caused by a parasitic worm found primarily in Africa. The worm (Onchocerca volvulus) is transmitted to humans as immature larvae through bites of infected black flies.
Researchers from LSTM's Research Centre for Drugs and Diagnostics have found a way of significantly reducing the treatment required for lymphatic filariasis and onchocerciasis from several weeks to seven days. By targeting Wolbachia, a bacterial symbiont that the filarial parasites need to live, the team has discovered a drug synergy that enables effective treatment over a shorter time.
In a small, randomized Phase I/II clinical trial (SAT1), researchers at University of California San Diego School of Medicine say a 100-year-old drug called suramin, originally developed to treat African sleeping sickness, was safely administered to children with autism spectrum disorder (ASD), who subsequently displayed measurable, but transient, improvement in core symptoms of autism.
Since 2007, the World Health Organization (WHO) has been reporting outstanding success in dealing with neglected tropical diseases (NTDs) with 1 billion people estimated to have received treatments in 2015.
Research teams from the National Institutes of Health and abroad have identified the first inhibitor of an enzyme long thought to be a potential drug target for fighting disease-causing parasites and bacteria.
SUGAR-based adjuvants from Australia are boosting the effectiveness of vaccines to target some of the world’s deadliest diseases.